Selection of Anti-Cancer Agent based on Radionuclide Cross Sectional Area used in Nuclear Therapy Technology

S.H. Dhobi¹

Section:Research Paper, Product Type: Journal-Paper
Vol.8 , Issue.6 , pp.1-5, Dec-2020

Online published on Dec 31, 2020

Copyright © S.H. Dhobi . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

Abstract :
Study the selection of cross sectional areas of radionuclide and its implementation in the medical field like nuclear therapy is the main objective of this work. For the selection of radionuclide cross section, two nuclear reactions (p, n) and (d, 2n) of Rh and Pd were taken. The observation shows the cross sectional area of (d, 2n) is higher than (p, n) during the reaction. Therefore this observation is beneficial for the selection and treatment of infected areas with more safety and accuracy.

Key-Words / Index Term :
Radionuclide, Cross Sectional Area, Infected Surface, Healthy Cell, Technology, Therapy, etc.

References :
[1] G. Bak, S.B. Selcuklu, H. Yap, “Medical Radioisotope Production in a Power-Flattened ADS Fuelled with Uranium and Plutonium Dioxides”, Science and Technology of Nuclear Installations, Vol. 2016, pp.1-11, Art. No. 5302176, 2016
[2] C.H. Yeong, M.H. Cheng, N.G.K. Hoong NG, “Therapeutic radionuclides in nuclear medicine: current and future prospects”, Biomedicine & Biotechnology, Vol.12, Issue.4, pp.34-35, 2014.
[3] E. A. Eliot, D. Hicks, L. E. Beghian, H. Halban, “Inelastic Scattering of Neutrons”, Physics Review, Vol.94, Issue.144, pp.50-70, 1954.
[4] M.A. Majali, A.R. Mathakar, S. Banerjec, G. Samuel, M.R.A. Pillai, “153Sm Complexes of Phosphonic Acid Ligands, Isotope Division”, Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India, pp.133-139, 2020.
[5] Y.E. Demidtchik, S.D. Kirinuk, “Radioiodine Therapy for Pediatric Patients with Thyroid Cancer, Research Institute of Radiation”, Medicine and Endocrinology, Minsk, Belarus, pp.158-161, 2020.
[6] F. Tárkányi, F. Ditrói, S. Takács, A. Hermanne, M. Baba, H. Yuki And A.V. Ignatyuk, “Investigation of Activation Cross Sections of Proton induced reactions on rhodium up to 70 Mev for practical applications”, arxiv, pp.1-20, 2020,
[7] A.J.M. Plompen, M.B. Chadwick, A.J. Koning, “Neutron Activation Cross-Section Measurements from Threshold to 20 Mev for the Validation of Nuclear Models and Their Parameters”, Vol.19, pp.3-50, 2015.
[8] Gilbert Gedeon, P.E. , Nuclear Characteristics of a Reactor CourseNo:N03-001 Lecture Note, pp.12-16, 2012.
[9] F. Tarkanyia, F. Ditroia, S. Takacsa, J. Csikaia, A. Hermanneb, S. Uddind, M. Babad, “Activation Cross Sections of Proton Induced Nuclear Reactions on Palladium up to 80 MeV”, Preprint submitted to Applied Radiation and Isotopes, Vol.114, Issue.128, pp.14-26, 2016.